BioLineRx (BLRX) Cash from Operations (2013 - 2026)

BioLineRx's Cash from Operations history runs 13 years deep, the most recent figure standing at 3200000.0 for Q4 2025.

• In Q4 2025, Cash from Operations rose 62.83% year-over-year to 3200000.0; the TTM figure through Dec 2025 stood at 8074000.0 (up 81.6% YoY), while the FY2025 annual figure was 8074000.0, up 81.6% from the prior year.
• Cash from Operations for Q4 2025 stood at 3200000.0, down from 2106000.0 in the prior quarter.
• The five-year high for Cash from Operations was 4991000.0 in Q4 2023, with the low at 14109000.0 in Q1 2024.
• The 5-year median for Cash from Operations is 6259000.0 (2021), against an average of 6218400.0.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations surged 187.82% in 2023, then slumped 272.51% in 2024.
• BioLineRx's Cash from Operations stood at 5503000.0 in 2021, then fell by 3.27% to 5683000.0 in 2022, then soared by 187.82% to 4991000.0 in 2023, then plunged by 272.51% to 8610000.0 in 2024, then soared by 62.83% to 3200000.0 in 2025.
• Business Quant data shows BLRX's Cash from Operations at 3200000.0 in Q4 2025, 2106000.0 in Q3 2025, and 177000.0 in Q2 2025.